20150818-Maybank_KERPL-Royal_Rumble_18页_871kb

Cordlife Group (CLGL SP) Summary

Core Information

• Share Price: SGD1.17
• Target Price: SGD1.56 (+33%)
• Market Cap (USD): 222M
• ADTV (USD): 0.4M
• Sector: Health Care
• Recommendation: BUY
• Location: Singapore

Key Points

• Bidding War for CCBC: A competitive situation is emerging among three contenders: Golden Meditech (GM), Zhongyuan Union Cell & Gene Engineering, and Nanjing Xinjiekou Department Store.
• Cordlife's Stake in CCBC: Cordlife owns a 13.4% fully-diluted stake in CCBC, which is highly valuable and likely to be a target for acquisition.
• Potential for Special Dividends: Cordlife could receive up to SGD150m in cash from the sale of its CCBC stake to GM, potentially enabling a special dividend.

Financial Overview

Valuation and Investment Outlook

• Current Valuation: Cordlife is undervalued at 18x ex-cash P/E, even without a takeover.
• Takeover Potential: A full general offer (GO) is required to secure Cordlife's stake in CCBC, as the conditional sale to GM may not be approved by shareholders.
• Target Price Rationale: The target price of SGD1.56 is based on a 28x core EPS and USD7/share for the CCBC stake.
• Fair Value Range: In a takeover scenario, Cordlife's fair value could range from SGD1.48 to SGD2.75, depending on the P/E multiple and CCBC stake valuation.

Takeover Scenarios

1. Direct Offer for CCBC Stake

• Pros: Cheapest option for buyers.
• Cons: Likely to trigger higher bids from other parties, and may not be sufficient to convince Cordlife's board to walk away from the conditional sale to GM.

2. Partial General Offer

• Pros: Less costly than a full takeover.
• Cons: Faces the same hurdle as a direct offer — the EGM vote on the sale to GM. Shareholders may not all benefit equally, and the offer must be pro-rated.

3. Full General Offer

• Pros: Guarantees control over CCBC stake, provides a strong platform for Asian growth.
• Cons: More expensive than partial offers.
• Estimated Cost: USD296m or c.USD18 per CCBC share at the target price.

Required Offer Price

• Minimum Offer: SGD1.62–2.09 to be taken seriously by Cordlife's shareholders.
• Reasoning: Based on Singapore's high healthcare valuations and the likely intensity of a bidding war for CCBC.

Risks and Considerations

• Chinese Market Risks: Potential market rout and currency devaluation in China could dampen PRC buyers' appetite.
• Legal and Approval Hurdles: Cordlife's conditional sale to GM is subject to shareholder approval, and any competing offer must reach shareholders before the EGM.
• Zhongyuan and Xinjiekou: These Chinese contenders have made unsolicited offers, but their financial commitments and intentions are uncertain.

Special Dividend Potential

• Estimated Cash: SGD150m from the sale of CCBC stake to GM.
• Dividend Yield: Up to SGD0.14 per share, which could yield 12% at the current share price.
• Ex-Cash P/E: 18x, indicating undervaluation.

Shareholder Considerations

• EGM Timing: Expected to be held in September or October.
• Shareholder Approval: Cordlife's shareholders must reject the sale to GM for a takeover to be viable.
• Escrow Commitment: Buyers must demonstrate financial commitment to convince Cordlife's shareholders.

Conclusion

Cordlife is currently undervalued, with potential for significant upside either through a takeover or via special dividends. A full general offer is necessary to secure its stake in CCBC, given the ongoing bidding war and the conditional sale to GM. The target price of SGD1.56 reflects its current valuation and the potential value of its stake in CCBC. Investors should remain watchful for developments leading up to the EGM and consider the likelihood of a full takeover.